MGMT Gene Promoter Methylation Analysis
MGMT methylation analysis can be used as a prognostic marker for survival from Glioblastoma (GMB) or as a predictive measure for response to chemotherapy
Research Use Product
Research Service
Early Detection/Screening
Diagnosis
Therapy Selection
Therapy Monitoring
Introducing QMethyl™ MGMT Gene Promoter Test As a Prognosis Biomarker
The Qmethyl™ MGMT Gene Promoter Methylation Test is a high-throughput quantitative approach that utilizes fluorescence-based real-time PCR (TaqMan) technology to determine the MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation status using methylation-specific probes. MGMT methylation analysis can be used as a prognostic marker for survival from Glioblastoma (GBM) or as a predictive measure for response to chemotherapy.
The assay can be used in clinical research in GMB studies
The assay can be validated in clinical labs to monitor the prognosis of GMB patients treated with TMZ (temozolomide)
Glioblastoma (GBM) is a primary malignancy of the central nervous system (CNS), appearing as grade 4 aggressive tumors.
Brain Tumor
Glioblastoma (GBM) represents 14% of all brain tumors.
GBM Diagnosis
In the United States alone, over 12,000 people are diagnosed with GBM each year, according to the American Cancer Society.
Standard Treatment
The standard treatment for GBM includes surgery followed by radiotherapy and chemotherapy (temozolomide, TMZ). TMZ suppresses tumor DNA replication.
MGMT (O-6-methylguanine-DNA methyltransferase) gene promoter methylation reduces the level of the MGMT enzyme, an important enzyme for DNA repair. Therefore, methylation of the MGMT gene promoter makes patients more responsive to TMZ chemotherapy, killing the tumor cells by damaging the DNA.
- It is estimated that 40 to 50% of malignant glioma patients have MGMT gene promoter methylation. Identification of this population benefits the prognosis and makes TMZ chemotherapy more effective.
- O-6-methylguanine-DNA methyltransferase (MGMT) reduces TMZ-induced cell death and weakens the chemotherapy effect. The expression of MGMT is inhibited by the methylation at CpG islands along the MGMT gene promoter.
- By measuring MGMT promoter methylation, the sensitivity of the tumor to TMZ can be evaluated.
- Many studies have indicated association of the methylation of the MGMT gene promoter region with better survival outcomes among the GBM patients treated with TMZ.
